In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Say Good-bye to the Family Farm

Executive Summary

Watson Pharmaceuticals Inc.'s purchase of Schein Pharmaceutical seems to confirm what generics industry experts have known for some time: the industry is consolidating at both the wholesaler and manufacturer levels. The purchase, for $674 million and the assumption of $240 million in debt, is the third time in the past year that a large generics maker has bought a rival. The deal puts Watson, now ranked number four in generics, in a race for first place with Teva Pharmaceutical Industries Inc., which has also been on a buying spree.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel